NRC FORM 374 U.S. NUCLEAR REGULATO	DRY COMMISSION PAGE1_OF _4_PAGES Amendment No. 19				
MATERIALS L	ICENSE				
Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.					
Licensee	In accordance with letter dated				
	February 20, 2007,				
1. Dukes Health System, LLC	3. License number 13-18703-01 is amended in				
d/b/a Dukes Memorial Hospital	its entirety to read as follows:				
2. 275 West 12th Street	4. Expiration date August 31, 2015				
Peru, IN 46970-1698	5. Docket No. 030-14065				
	Reference No.				
 6. Byproduct, source, and/or special nuclear material A. Any byproduct material A. Any permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Any byproduct material permitted by 10 CFR 35.300 D. Any byproduct material permitted by 10 CFR 35.11 E. Depleted Uranium Hetal 	 8. Maximum amount that licensee may possess at any one time under this license A. As needed B. As needed C. As needed (not to exceed 1 curie of iodine-131) D. As needed C. 4 shields not to exceed 25 pounds each 				
9. Authorized Use:	**				
A. Any uptake, dilution and excretion study permitte	d by 10 CFR 35.100.				
B. Any imaging and localization study permitted by 10 CFR 35.200.					
C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.					
D. <u>In vitro</u> studies.					
 E. For shielding in ADAC Laboratories Transmissior MCD/AC. 	n Line Source Housing VANTAGE device Model No.				

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMIS	SION PAGE 2 of 4 PAGES
	License Number 13-18703-01
MATERIALS LICENSE SUPPLEMENTARY SHEET	Docket or Reference Number 030-14065
	Amendment No. 19
	<u>. </u>
CONDITIONS	
10. Licensed material may be used at the licensee's faciliti	ies located at 275 West 12th Street, Peru, Indiana.
11. Radiation Safety Officer: Marvin Dean Dziabis, M.D.	
12. Licensed material is only authorized for use by, or und	ler the supervision of:
A. Individuals permitted to work as an authorized use	er in accordance with 10 CFR 35.13 and 35.14.
B. The following individuals are authorized users for	medical use as indicated:
Authorized Users	Material and Use
Marvin Dean Dziabis, M.D.	1000 FR 35.100, 35.200 and 31.11.
Marvin Dean Dziabis, M.D. Dean Gifford, M.D. Greg Quin, M.D.	10 CFR 35.100, 35.200 and 31.11.
Greg Quin, M.D.	10 CFR 35,100, 35,200 and 31.11.
Sophia Yeh, M.D. 🔟	10 CFR 30 00, 35.200, 35.300 and 31.11.
Alan S. Cooperman, D.O.	10 CT 100, 35.2 Q , 35.300 and 31.11.
Joseph R. DeCamp, M.D.	5,100, 35.200, 35.300 (for iodine-131,
	quantities equal to or less than 33 millicuries).
Brett A. Hagedorn, M.D.	10 CF, 35.100, 35.200, 35.300.
John Pasalich, M.D.	10 CFR 35.100, 35.200, 35.300.
Stephen R. Phillip, M.D.	2 CT 35.100, 35.200, 35.300.
Marc Thomas, M.D.	10 CFR 35.100, 35.200, 35.300.
Diane D. Daly, M.D.	10 CFR 35.100, 35.200, 35.300.
	10 CFR 35.100, 35.200, 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries).
Christopher M. Kowalski, M.D.	10 CFR 35.100, 35.200
John L. Bormann, M.D.	10 CFR 35.100, 35.200, 35.300.

NRC FORM 374A U.S. NUCLEAR REGULATORY COM	MISSION PAGE 3 of 4 PAGES
	License Number 13-18703-01
MATERIALS LICENSE SUPPLEMENTARY SHEET	Docket or Reference Number 030-14065
	Amendment No. 19
Authorized Users	Material and Use
Michael E. Parker, M.D.	10 CFR 35.100, 35.200, 35.300.
Michael W. Tanksley, M.D.	10 CFR 35.100, 35.200, 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries).
Andre B. Stovall, M.D.	10 CFR 35.100, 35.200, 35.300.
Pamela Lee Strange, M.D.	10 CFR 35.100, 35.200, 35.300.
- 12	E 10-CKR 35.100, 35.200, 35.300.
James C. Wehrenberg, M.D.	10 CFR 35.100 and 35.200.
James A. Arata, M.D.	10 CFR 35,10 35.200, 35.300.
David B. Janizek, M/D.	10 CFF 100, 35.200, 35.300.
Christine A. Tremaer, M.D.	10 Contraction of sodium iodide-131, 10 Contraction of sodium iodide-131 in
s second	the sequel to optess than 33 millicuries).
Randall J. Phillips, D .D. John R. Kim, M.D.	10 CFR 35 100, 35.290, 35.300.
	quantities equal to or less than 33 millicuries).
Gina w. Hook, M.D.	CFR 35.100 and 35.200.
Richard W. Sibley, M.D.	10 CFR 35.100, 35.200, 35.300.
Dakshesh S. Patel, M.D.	10 CFR 35.100 and 35.200.
Eric V. Heatwole, M.D.	10 CFR 35.100 and 35.200.
Shilpa S. Kashyap, M.D.	10 CFR 35.100 and 35.200.
Deepchand Bajpai, M.D.	10 CFR 35.300.
Rao V.P. Mantravadi, M.D.	10 CFR 35.300.

NRC FORM 374A	U.S. NUCLEAR REGULATORY	COMMISSION		PAGE	4	of	4	PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET			License Number 13-18703-01					
			Docket or Reference Num 030-14065	ber				
		Amendment No. 19)					
Authorize	d Users	<u>Mate</u>	rial and Use					
James G	ates, M.D.	10 C	FR 35.300.					
Stephen	Beyer, M.D.	10 C	FR 35.300.					
Shawn Jo	ohnson, M.D.	10 C	FR 35.100, 35.200,	35.300	•			
13. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."						0 CFR		
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance. G (μ						on of		
 15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statemente, representations, and procedures contined in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection protection makes the statements, representations, and procedures in the licensee's application as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission regulations shall be multipletense to statements, representations, and procedures in the licensee's application correspondence are more restrictive than the regulation dated Rebruary to 2005. A. Application dated Rebruary to 2005. 								
		FOR THE L	I.S. NUCLEAR REG	ULATC	RY	CON	IMIS	SION
DateMAR 2	7 2007		Mullauer, M.H.S. Licensing Branch	uer	.			